阿立哌唑与氯氮平治疗首发精神分裂症对照研究.docVIP

阿立哌唑与氯氮平治疗首发精神分裂症对照研究 目录 TOC \o 1-9 \h \z \u 目录 1 正文 1 文1：阿立哌唑与氯氮平治疗首发精神分裂症对照研究 1 1 对象与方法 2 2 结果 4 3 讨论 5 文2：阿立哌唑与利培酮治疗首发精神分裂症对照研究 5 1 对象与方法 6 2 结果 7 3 讨论 8 参考文摘引言： 9 原创性声明（模板） 9 文章致谢（模板） 10 正文 阿立哌唑与氯氮平治疗首发精神分裂症对照研究 文1：阿立哌唑与氯氮平治疗首发精神分裂症对照研究 A control study of aripirazole and clozapine in the treatment of fitepisode schizophrenia 【Abstract】 Objective To explore the curative effects and safety of aripiprazole in the treatment of fitepisode schizophrenia. Methods 74 patients with fitepisode schizophrenia were randomly divided into research(n=36, took aripiprazole ) and control(n=38,did clozapine) for 8 weeks. Curative effects were assessed with the Positive and Negative Syndrome Scale(PA) and advee reactio with the Treatment Emergent Symptom Scale(TESS), respectively. Results At the end of the 8th week, total rates were % in the research and % in the control group, which showed therapeutic equivalence. In corresponding period score of the PA had no difference between the 2 groups(P); intragroup compariso showed very significant difference between pre and posttreatment(P). Improvements of cognitive function and negative symptoms were more significant(P) and incidence of advee effects lower in the research than in the control group. Conclusion Aripirazole has therapeutic equivalence to clozapine in fitepisode schizophrenia, significantly improves cognitive function and negative symptoms and has higher safety and better compliance. 【Keywords】 Fitepisode schizophrenia; ariprazole；clozapine；the PA; the TESS 阿立哌唑是喹诺啉酮的衍生物，是新一代非典型抗精神病药物，主要通过对D2和5羟色胺1A（5HT1A）受体的部分激动作用以及对5HT2A受体的拮抗作用而共同起效［1］，能有效改善精神分裂症患者的阳性、阴性症状和认知功能，且较少或不引起传统抗精神病药物所致的锥体外系不良反应。为探讨阿立哌唑治疗首发精神分裂症的疗效及安全性，我们与氯氮平进行了对照研究，现将结果报告如下。 1 对象与方法 对象 选取2004年8月1日～2005年10月31日在我院住院的74例首发精神分裂症患者为研究对象。入组标准：（1）符合《 中国 精神障碍分类与诊断标准》第3版（CCMD3）精神分裂症诊断标准；（2）首次发病，年龄15 a～40 a，性别不限；（3）入组前未服用任何抗精神病药；（4）潘氏量表（PA）总分≥60分。排除标准：（1）儿童、妊娠期及哺乳期妇女；（2）伴有严重脑、心、肝、肾脏等躯体疾病、血液病、肿瘤或青光眼患者。 方法 分组 将入组病例随机分为研究组36例和对照组38例。研究组男